GILEAD Grants

Biomedical Research

2025 CALL:

Receipt of proposals from June 1st to June 30th, 2025, via the website: www.BecasGileadInvestigacion.es

Language of Project presentation (page 12): All the information presented for evaluation must be sent in English (research project report and CV of all investigators).

Beneficiary Requirements (page 4): Non-profit organisations and patronage beneficiary organisations listed in Articles 2 and 16 of the 49/2002 Law of 23 December and Health Research Institutes and Public Research Consortiums that are members of Public Research Bodies in the area of health sciences.

Type of project (page 5): National research programmes in the areas of HIV, Hemato-Oncology and Medical Oncology with an implementation period of no more than 24 months are that are performed in Spanish Healthcare Centres.

Type of categories by research group (page 5):

- Research group led by Investigators born in 1985 or later.
- Research group led by investigators born before 1985.

Project Exclusion (page 9): Among other aspects, projects shall be excluded:

- Those evaluating marketed or in development drugs, regardless of whether they are drugs or other type of treatments owned by GILEAD, another pharmaceutical company, or another academic body or institution.

Maximum number of projects to be presented (page 12): A maximum of two projects may be submitted per therapeutic area and healthcare center (Principal Investigator affiliated healthcare center).

Each principal researcher may only present one proposed Research Project (page 12).

Validation of submitted projects (page 13): *The first week of July, it will be verified that projects submitted meet the requirements established in the terms and conditions of the call. If they do not comply, the applicant will be notified. A period of 10 calendar days will be opened for allegations.*

Evaluation system (page 13): Projects received shall be evaluated by the Carlos III Health Institute, which shall act independently and according to the principles of transparency, objectivity and equal opportunities.

Maximum number of grants to be awarded per applicant entity (page 12): At most, only one project may be granted per therapeutic area and healthcare center (Principal Investigator affiliated healthcare center).

Two projects from the category of "research groups led by investigators born in 1985 or later" will be selected for funding (page 5), which will be the ones with the highest scores regardless of the area of research. Subsequently, the rest of the projects will be selected based on the score obtained and the availability of funding according to the area of research, regardless of the age of the principal investigator.

Budget for the grant (page 10): Variable amount that may not exceed 55,000 euros per project. This aid shall be compatible with the obtaining of other subsidies, aid, income or resources of a public or private nature.

INTRODUCTION

In view of the need to **acquire, report and apply scientific knowledge** to health care activities for the purpose of achieving progress and improving patients' lives, **GILEAD SCIENCES, S.L.U., (GILEAD) has actively implemented a policy to promote and support** key research projects and educational/scientific programs in therapeutic areas of interest (such as HIV/AIDS, cancer hemato-oncological, liver, and other viral diseases, as it considers that there are unmet needs in these health care areas.

Accordingly, GILEAD has announced the ***"The 12th Call for Gilead Biomedical Research Grants in HIV, Hemato-Oncology and Medical Oncology***" in order to foster the development of health care research in these areas within Spain.

The call is intended to promote **new research projects** that will benefit patients, society, and the scientific community through the award of funds to be used for the projects.

This financial grant initiative for research activities, which is sponsored by GILEAD, is in keeping with public policies to foster and promote scientific and technical research, particularly in the above biomedical areas, as well as to encourage collaboration and cooperation among the various players in the health sciences (private institutions, public research agencies, and National Health Service facilities), in order to **identify synergies among research groups that will allow the results to be used in improving public health**.

This call is also consistent with other investment efforts related to applied R&D in the health sciences promoted by the Spanish Ministry of Health, Social Policy and Equality.

Consequently, GILEAD intends to contribute, through this initiative, to the promotion and development of public and private cooperative instruments in health care research in areas such as HIV, Hemato-Oncology and Medical Oncology.

Therefore, an agreement has been signed with the Instituto de Salud Carlos III management regarding their participation in the process to evaluate research projects submitted as part of this call, as well as regarding the support of the Ministry of Health, Social Policy and Equality.

General Terms and Conditions

One. Purpose

These terms and conditions are intended to establish the rules, requirements and specifications for GILEAD grants awarded as part of the ***"The 12th Call for Gilead Biomedical Research Grants in HIV, Hemato-Oncology and Medical Oncology".***

These funds will be awarded through a competitive procedure that reviews all applications submitted, under terms that guarantee the principles of publicity, transparency, objectivity, equality and non-discrimination in the grant procedure.

In this competitive procedure, the financial grants are awarded after comparing the applications submitted to establish the priorities thereof, in accordance with the objective review criteria defined in section 2.2 of the Grant Award and Notification document, in which the funds are awarded to the applications with the highest scores **(upper limit of 55,000 euros per project)** until all available financial resources are assigned under the terms described in Condition Four of this call.

The grant awards will be formalized by signing a Cooperative Agreement between GILEAD and the grant recipient under the terms set forth in the applicable legislation.

Two. Grant Recipient Requirements

1. Proposals for research projects in Spain may benefit from the grants included in this call for research projects to be conducted in Spanish health care centres and that originate at the non-profit institutions and sponsored grant recipients listed in Articles 2 and 16 of Law 49/2002, of December 23, covered by the tax system for non-profit organizations and the tax incentives for sponsor organizations, provided that the requirements of the provisions of Article 3 of this law are met. In particular, and considering the provisions stated in the aforementioned regulation as well as the scope of this grant program, the following institutions are included:

- Foundations.
- Associations declared of public usefulness
- Federations and associations of non-profit entities referenced in the paragraph above
- Public universities
- Public research agencies under the auspices of the central government.

2. Likewise, the grants can be awarded to health research institutions and to public research consortiums under the auspices of public research agencies in the field of health sciences. In such situations, the legislative or regulatory requirements that are applicable to such institutions shall be considered.

3. The grants may not be awarded to natural persons, but only to the institutions described above, which must submit the documentation listed in the grant procedure described in the Grant Award and Notification section hereof.

4. Projects submitted by a researcher who had been part of the research team of a project that received a grant in the previous year's call will be excluded from this 12th call.

Three. Research Group Characteristics and Categories

All proposals submitted must fall into one of the following research group categories:

- **Groups led by investigators born in 1985 or later**, whose scientific production allows them to be considered as having the potential to become highly competitive groups; they must submit differentiated, innovative research proposals not involving a split of pre-existing groups.
- **Standard groups (led by researchers born before 1985)** which must comply with the general conditions set out in the different sections, without any other specific nature.

Four. Requirements for Research Project Proposals

a) Research lines allowed

Proposals submitted hereunder may only relate to research projects taking place in national territory and with an execution period not above 24 months. This period shall be counted from the date on which the business cooperative agreement for activities of general interest alluded to in the Grant Award and Notification section of this website are signed.

The projects must fall within one of the research lines defined below:

HIV:

1. **Research to improve knowledge and the care cascade in specific populations of PLWH:** Innovative projects carried out in specific populations where there are epidemiological and clinical knowledge needs, such as:
    - older people (aging of PLWH)
    - women
    - transgender people
    - migrant population
    - Chemsex users
    - Sex workers

- homeless people

a. Innovative proposals that evaluate the epidemiological characteristics and clinical needs of these populations.

b. Innovative proposals that help improve the diagnosis of HIV infection and the linkage to the healthcare system of these populations.

c. Innovative proposals to evaluate and improve the management of certain comorbidities in these populations, such as possible metabolic alterations, neuropsychiatric and psychosocial comorbidity, cardiovascular comorbidity, or co-infection with other viruses, specifically hepatitis B virus.

2. **Research on innovative care strategies for the improvement of early diagnosis and follow-up of PLWH:**

   a. Strategies for detecting HIV infection and reducing late diagnosis in at-risk populations.

   b. Strategies that reduce the frequency of visits, improve the quality of care for PLWH, and optimize the use of health system resources.

   c. Strategies to evaluate the management of hepatitis B virus co-infection in PLWH.

3. **Research on improving access and implementation of PrEP:**

   a. Identification and creation of fast-track access circuits to PrEP for specific populations at high risk of HIV infection and with lower current access to it: sex workers, cisgender women, transgender people, migrant men who have sex with men (MSM), Chemsex users, and adolescents.

   b. Strategies that reduce the frequency of in-person visits: proposals for innovative circuits and tools (self-sampling, telepharmacy, telemedicine…) that reduce the frequency of in-person follow-up visits for PrEP users.

   c. Innovative models for implementing PrEP with collaborative work circuits that bring PrEP closer to current or potential users: design of integrated work schemes between primary care, nursing, NGOs, and infectious disease specialists (hospital or STI clinics) focused on improving access and user experience.

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded.

Hemato-Oncology: B-cell non-Hodgkin lymphomas (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma, follicular lymphoma).

- Automation and implementation projects for the improvement of existing process for treating with CAR-T therapy.
- Projects to facilitate the identification of patients eligible for treatment with CAR-T and to improve the connection between different levels of care to expedite CAR-t therapy.
- Research projects addressed at improving comprehensive patient management programs and healthcare coordination of CAR-T treatment.
- Clinical projects related to the study of prognostic variables and predictive factors, including image techniques or laboratory tests, innovative applications of new technologies like Artificial Intelligence, associated with CAR-T cell therapy.
- Characterization of mechanisms of resistance to CAR-T cell therapy.
- Studies related to the economic burden of disease as well as cohort studies investigating routine clinical practice with CAR-T therapy.
- Preclinical and translational studies on predictive factors and mechanisms of resistance to CAR-T therapy.

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded.

Medical ONCOLOGY (SOLID TUMORS):

- Clinical or clinical-translational projects in patients with solid tumors in which innovative applications of new technologies, such as artificial intelligence applied to clinical or molecular data are developed.
- Clinical or clinical-translational projects in solid tumors related to the study of prognostic variables and predictive variables.
- Follow-up studies of patient cohorts or case-controls.

Projects will be led by a specialist in Medical Oncology, and it will be valued that the research team is multidisciplinary and that it includes specialists in Medical Oncology from multiple centers.

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded.

b) Participation modalities

The research project proposals may be submitted in one of the following modalities:

a) **Single-center study**: project submitted by a single applicant, in accordance with the provisions in Term 2 hereunder, and that will be conducted at a single health care center. Such projects may be subcontracted, although the grant recipient must ensure that it is subcontracted in accordance with all applicable legislation and regulations.

b) **Multicenter study**: project requested by a single applicant, in accordance with the provisions in Term 2 hereunder, and that will be conducted at various health care centers. The coordinator center must report the participating centers in the application.

c) Excluded scopes

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded.

d) Ethical-legal aspects of research projects

Research projects applying for the grant must adhere to the fundamental principles established in the Declaration of Helsinki, the Convention on Human Rights and Biomedicine of the Council of Europe, and the Universal Declaration on the Human Genome and Human Rights, and must comply with the requirements established in the Spanish legislation on medical research, personal data protection and bioethics, in accordance with Law 14/2007, of July 3, on biomedical research and other requirements established in the Spanish legislation on these matters.

All projects must comply with the legal and regulatory provisions in effect and any provisions that modify or develop them, in particular:

a) Projects that involve human research or the use of biological samples of human origin must comply with the provisions of Law 14/2007, of July 3, on biomedical research and all other current legislation on the matter.

b) Projects that involve clinical trials must comply with the provisions of Royal Decree 1090/2015, of December 4.

c) Post-authorization observational studies on medicines for human use in accordance with the Royal Decree 957/2020, of November 3.

Five. Grant funding

The "***The 12th Call for Gilead Biomedical Research Grants in HIV, Hemato-Oncology and Medical Oncology***" sponsored by GILEAD **consists of €950,000 to be used to fund research projects that meet the requirements and conditions described in these Terms and Conditions. For HIV area, €385,000 will be allocated (30% will be dedicated exclusively to the Research**

on improving access and implementation of PrEP topic); €110,000 for Hemato-Oncology and €440,000 for Medical Oncology).

After the evaluation of the projects, two projects of the category "research groups led by investigators born in 1985 or later" will be selected for funding, which will be the projects with higher score obtained, independently of the research area. The rest of the projects will be selected based on the obtained scored and the availability of funding according to the area of research, regardless of the age of the principal investigator.

The grant awarded hereunder shall consist of **financial contributions** with a variable amount not above 55,000 euros per project and which includes the costs of administrative management.

The award of this grant must be compatible with any other subsidies, grants, income or resources of a public or private nature used to fund the research project submitted hereunder, provided that the amount already received, whether itself, or in addition to the amount of grant proposed hereunder, does not exceed the total cost of the research activity under consideration. Precisely for this reason, the grant award will consider the existence of other funding sources available to the applicant's research team, by virtue of the information provided on the Application Form.

In the project review and review process, the Instituto de Salud Carlos III Review Board shall be entitled to adjust the budget itemization listed in such projects to the standards defined in calls by such institution.

If sufficient funds are freed up due to waiver by one or more of the beneficiaries following a grant award, GILEAD may propose that the grant be awarded to another grant recipient based on the score order obtained in the final reports prepared by the Technical Review Boards, which must accept them under the same terms indicated herein.

Six. Items eligible for grant

Grants awarded hereunder must cover costs directly related to the execution of the activities of the research project submitted by the potential grant recipient, with the scope and limits set forth herein.

However, only activities considered consistent with the specific objective or purpose of the non-profit organization applying for the grant will be considered eligible for funding.

In particular, the following project execution costs are considered eligible for grants:

a) Costs for instrumentation and depreciation of newly acquired scientific-technical equipment, to the extent and during the period in which it is used for the research project

b) Costs for consumables and supplies necessary for project execution

c) Costs for contract research

d) Travel and per diem for research team members, duly proven, including investigator visits and stays directly related to the project, etc.

e) General additional costs directly derived from the project or activity

f) Staff costs directly and exclusively related to performance of the subsidized research project (maximum of one year).

Under no circumstances may the amount of the grant received hereunder be used to directly fund research team staff in their health care activities and, therefore, the entities, institutions or agencies to which such staff reports professionally are responsible for payment of their compensation. Research team staff may be compensated with funds obtained hereunder in accordance with the time devoted exclusively to the project.

Likewise, costs to acquire scientific-technical equipment are also not considered eligible for funding.

GRANT AWARD AND NOTIFICATION

1. Application submission

All grant applications must be submitted online at www.BecasGileadInvestigacion.es.

In this 12th call **all information must be submitted in English** (Research project report and CV of all investigators) and, therefore, no projects submitted in any other language will be reviewed.

Each **principal investigator may submit only one research project proposal**. A maximum of two projects may be submitted per therapeutic area and healthcare center (Principal Investigator affiliated healthcare center).

Only one project at most may be awarded per therapeutic area and healthcare center (Principal Investigator affiliated healthcare center)**.**

For each application, **indicate the category of research group in which you are participating** (group led by investigators born in 1985 or later or group led by investigators born before 1985).

The information required for an application to be evaluated will be as follows:

- Research project report in accordance with the template provided.
- Abbreviated Curriculum Vitae (CVA-ISCIII), automatically generated from the CVN editor (http://cvn.fecyt.es/editor) or from any institution certified in the CVN standard of the FECYT that offers the CVA-ISCIII service, of the principal investigator and the rest of the collaborators.

- Authorization from the director of the health care site where the project will be conducted, in accordance with the template.
- Articles of association of the grant applicant.
- Power of attorney for the signer from the institution.
- Registration of the institution in the respective registry.
- Certificate of the Declaration of Public Utility in the case of associations.

All applications and respective appendices must be submitted by the interested parties online at www.BecasGileadInvestigacion.es from June 1st to June 30th.

Any application submitted after the deadline will be excluded from this procedure, and the grant applicant will be notified of such fact by certified means. If the applications are incomplete when submitted, such situation will be reported to the grant applicant and a deadline of ten calendar days will be given to correct the application under the risk of being excluded from this call.

2. Validation of Proposals received

Once the call has closed, during the first week of July, it will be verified that the applications submitted meet the requirements established by the Terms and Conditions of the call.

If they do not comply, the applicant will be notified. A period of 10 calendar days will be opened for allegations.

If they are submitted incomplete, the applicant institution will be notified, and a period of 10 days will be opened to modify them, at risk of being excluded from this call for applications.

3. Procedure, evaluation Criteria and Competent Bodies for Evaluation of proposals

3.1 Procedure

Projects received will be reviewed by the Instituto de Salud Carlos III, which will act independently and in accordance with the principles of transparency, objectivity and equality of treatment, in accordance with the following procedure.

For this 12th call, the Instituto de Salud Carlos III has brought the review process to the international level, as in the previous edition, and will include international reviewers.

The research project proposals will undergo a two-phase review process.

The **first phase will consist of a scientific-technical review** of each project that will be carried out individually by at least two international experts.

These experts will be selected by the Instituto de Salud Carlos III and will confidentially and independently issue a review report on each proposal. Once the individual reports are analysed, a scientific-technical synthesis report will be prepared by independent experts.

The **second phase will consist of a panel review process** for all proposals by a Technical Review Board.

The Technical Review Board appointed by the ISCIII **will prepare a final report** for each proposal describing the most relevant aspects of the reviews carried out in the first phase and issue, in a consensus manner, a list of the proposals in order according to the score obtained using the review criteria set forth in the terms and conditions for the call.

3.2 Scientific-technical review criteria for the proposals:

a) Research team review:

The following will be reviewed for both the principal investigator and the rest of the team: academic record; professional merits (publications, research project funding, experience, mobility, national and international collaborations, health care activity), and candidate suitability for the tasks to be performed.

b) Project assessment:

The project will be assessed with regard to the following: quality, viability, relevance, interest, applicability and transfer; project capacity to improve disease prevention, diagnosis and treatment; impact; technology and outcome dissemination and transfer plan.

The review process is expected to be carried out by **four Technical Review Boards** (TRB) composed of national and international experts to assess the different research areas. Depending on the number of applications received, the number of technical committees could be adjusted to meet the needs.

These boards will be composed of a chair and a number of experts that will vary according to the number of proposals. The chair of each board will assign each proposal to **two reviewers for scientific-technical review from among experts unrelated to the board** and will likewise appoint, from among the board members, those responsible for preparing the synthesis reports.

All synthesis reports will be prepared by board members, and each board member will be assigned a similar number of proposals.

A board will be created to manage the review of proposals affected by **conflicts of interest** as a means to ensure the neutrality, transparency and objectivity of the process ("Technical Conflict of Interest Board").

Proposals will be understood to have a conflict of interest and, therefore, will be managed by this board whenever a board member has a direct or indirect relationship or interest, whether personal (by virtue of a family bond), economic, scientific, educational training, in particular the following:

- When the proposal is sponsored by a grant applicant in which the reviewer is involved, whether as a result of a professional dependent relationship, or by virtue of any other form of direct or indirect assistance.
- When the proposed award could have some kind of financial impact for the reviewer.
- When the proposal could interfere with the scientific interests of the reviewer in question.

In general, explicit or potential conflicts of interest will be identified by the chairs of the two Technical Review Boards prior to the reviewer assignment process.

In any case, for the purpose of safeguarding neutrality and independence in the review process, the Instituto de Salud Carlos III will ensure that experts participating in the proposal review process sign the "Ethical Review Commitment" requiring that they abstain from reviewing proposals in which there is a conflict of interest. Hereunder they also agree to maintain absolute confidentiality of all information to which they have access and the entire review process.

4. Proposed award

Once the proposals have been reviewed by the panel, the result of the review and the prioritized lists of project proposals will be sent to the Selection Board, licensed body, composed of the following:

- Subdirector General for the Review and Promotion of Research or the person who substitutes him/her.
- An official from the Subdirectorate General for the Review and Promotion of Research who will act as secretary.
- Chairs of the Technical Review Boards.

The decisions made by the Technical Review Boards cannot be appealed.

The Selection Board will confirm that the review process has been properly executed and, in view of the prioritized list of research project proposals and the budget allocated in the conditions, will prepare a report listing all proposals considered eligible, in particular, listing the fundable budget, according to criteria of maximum efficiency in the assignment of available financial resources. This report will be sent to GILEAD along with the meeting minutes, under conditions to ensure its confidentiality.

5. Grant Award and Notification to Grant Applicants

The Selection Committee will prepare an individual report per project, with details on the acceptance/denial of the application as well as the key points from the evaluation. These

reports will be sent by the ISCIII to GILEAD, the latter being responsible for posting them on the website of the Grants Program BecasGileadInvestigacion@gilead.es . Each resulting report will be available to the respective investigator responsible for the project that applied for the grant. If the investigators request additional reasons from GILEAD, ISCIII will inform them of the details included in the report to the investigators. GILEAD will approve the grant award based on the content of the Report/Proposal prepared by the Selection Committee described above.

Interested parties who have been notified of the grant award will have a term of 15 calendar days to notify GILEAD by certified means of their acceptance of the grant awarded under the terms and in the amount proposed.

If the above procedure has not been completed within this deadline, it will be understood that the grant awarded has been waived.

6. Signing of the Cooperative Agreement between GILEAD and the Grant Applicant

Once the grant has been expressly accepted, GILEAD will send the grant recipient two signed copies of the Cooperative Agreement used to govern execution of the research project selected. One of the copies of the Cooperative Agreement, duly signed by the legal representative of the grant applicant, must be sent to Gilead within 30 calendar days.

By signing the aforementioned agreement, the grant applicant assumes the following obligations:

a) Execute the project within the terms and deadlines described in the documentation submitted, without prejudice to any modifications imposed with regard to the fundable budget, based on the decision regarding grant award.

b) Notify GILEAD of any specific, duly justified circumstance that would involve changes in the technical or financial conditions taken into account for the grant award and that could require a modification in the approved project. In this case, the changes must be requested before the 24-month deadline for project execution is completed and will only be authorized if the objectives or essential aspects of the project are not lessened. Deadline extensions for the project execution will be authorized only in exceptional cases.

c) Declare that no project funds or funding sources other than those stated on their application have been obtained.

d) Notify GILEAD of the award of any other subsidy, aid or funding source that it could receive for the same project after the agreement has been signed. This fact could lead to a modification in the fundable budget awarded, if the finally funded amount received were to require it under the provisions of Condition Three hereof, it being necessary to refund the excess amount received.

e) Perform regular follow-up of project development to ensure that it meets the work plan proposed in the application. A final report must be prepared by the project's principal investigator to provide a detailed description of the objectives and results achieved in the research and **must be submitted by email to the address BecasGileadInvestigacion@gilead.es** within 30 calendar days after the end of the project execution deadline. The agreement may also allow such results to be presented at a personal meeting to which they may be called along with other organizations awarded grants hereunder.

f) Include an express reference to GILEAD participation in its funding through the Gilead Biomedical Research Grants Program: in particular, the following text must be included next to the Gilead logo: "*With assistance from the Gilead Biomedical Research Grants Program*". However, the grant applicant is obliged to report to the company, sufficiently in advance, of any public communication event related to the results obtained through the research project subject to grant hereunder. All the above is understood to be without prejudice to the ownership of any intellectual property rights arising from execution of the project, which will be held by its authors under the terms set forth in the applicable legislation. However, the authors shall provide express consent for GILEAD to cite them under the same condition, both on its website and, where applicable, in any other publication of the Company.

g) Submit a copy demonstrating costs corresponding to the items that comprise the fundable budget approved for execution of the research project, if required by GILEAD. For such purpose, invoices must be submitted to prove all costs and payments made, along with any other documentation that can be used to prove that payment has been made by the grant applicant according to usual business practice.

h) Keep the supporting documentation for both the grant payment from GILEAD and the use of the funds received for a six-year period as of submission, for the purposes of any verification and control activities.

i) Cooperate actively with GILEAD if necessary, to certify before the tax authorities any situation regarding the signing and compliance with the Cooperative Agreement, in order to promote the application of the tax system set forth in Article 25 of Law 49/2002, of December 23, with regard to the amount provided by GILEAD to fund the research activities described therein.

j) Return all or part of the grant amount received if the project is not executed, whether in whole or in part, the research project funded, or its execution is not demonstrated under the terms described herein.

7. Grant payment

The grant approved by GILEAD will be paid as a lump sum to the grant recipient within 30 calendar days as of date on which the collaboration agreement alluded to in the preceding point is signed.

Payment will be made by bank transfer to the account designated by the grant applicant on its application or, where applicable, in the agreement itself.

Follow-up and disclosure of results by GILEAD:

GILEAD reserves the right to perform regular follow-up on the progress of the research projects by the grant applicants. A final report of the research project shall be submitted to GILEAD the month after the date on which it ends.

The results and conclusions reached in this report will be subject to presentation at a public meeting convened for such purpose by GILEAD, which may require the participation of the principal investigators (or, where applicable, of some other member of the research team) responsible for execution of the respective research projects.